Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle
Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.
You may also be interested in...
Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.
More Phase III trials announced from Alexion and Novartis, while Karyopharm investigates potential of repurposed cancer therapy.
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.